Oncolytics Biotech Inc T.ONC

pfizer news

[spesestsemper]

2024-05-01 | NYSE:PFE | Press Release | Pfizer Inc (stockhouse.com)

February 2024. Pfizer hosted a meeting with the investment community where it outlined its strategic priorities for its Oncology organization. Pfizer’s Oncology portfolio is focused on three core scientific modalities: small molecules, ADCs, and bispecific antibodies, including other immuno-oncology biologics; and is focused on expanding its leadership in four main cancer types: breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers. By 2030, the company anticipates eight or more potential blockbusters in Oncology alone.

[spesestsemper]

New Drug Development Pipeline: Pfizer's Medicine, Vaccine Discovery | Pfizer

[Noteable]

March 04, 2024 - IRA Drives Pfizer’s Decision to Focus on Biologics, Not Small Molecules   https://www.biospace.com/article/ira-drives-pfizer-s-decision-to-focus-on-biologics-not-small-molecules/

[canadafan]

Can you please translate that small molecule/ biological significance to Onc relevance. i am not a doctor & as such, can not relate to either of the two. My assumption it is good news for onc/ pfizer collaborations? please exapand ? regards.

[Noteable]

Most all of my previous posts have described the significance of the distinctions. All you have to do is go over what I have posted already to learn the difference, including the geo-political reasons and significance of the IRA in shifting the USA biopharma industry towards biologics.

[Noteable]

May 06, 2024 - Pfizer Inc. (NYSE: PFE) today announced that Andrew Baum, M.D., will join the company as Chief Strategy and Innovation Officer, Executive Vice President. Dr. Baum will be a member of Pfizer’s Executive Leadership Team reporting to Chairman and Chief Executive Officer, Dr. Albert Bourla. He joins Pfizer from Citi, where he served as Head of Global Healthcare, Managing